This is only compatible with IE 8 and later, so browse at your own risk. Or upgrade. Internet Explorer は IE8 以上 推 奨。 そ れ 以前 の ブ ラ ウ ザ を ご 使用 の 方 は 最新 版 に ア ッ プ グ レ ー ド し て く だ さ い。
M / SUNNY
A biotech company in Fukuoka prefecture said Tuesday that it would begin human clinical trials of a drug to treat COVID-19 in 2021.
Bonac Corp. , in Kurume, Fukuoka Prefecture, said it has developed 72 applicants for the nucleic acid drugs and tested their effectiveness against respiratory disease caused by the novel coronavirus, in joint studies with the Institute of Health and Environmental Sciences of Fukuoka since June.
Ten of the applicants were found to be effective in “dramatically reducing replication” of the virus, proving the effectiveness of those opposed to COVID-19, according to the startup.
The team reduced the number of applicants from 10 to 3 who are very strong in the human frame and can be effective even in small numbers.
After deciding on one of them through non-clinical trials, human clinical trials will be introduced next year.
The potential drug may also be developed for the remedy for Middle East respiratory syndrome, or MERS, and severe acute respiratory syndrome, or SARS, either of which are similar to COVID-19 and are still hopeless, Bonac has stated.
The startup, established in 2010, said that through its “RNA interference technology,” it will try to create a drug capable of breaking down coronavirus genomic RNA and inducing antiviral effects in inflamed patients.
DNA and RNA, together nucleic acids, can be discovered in the cells of all living organisms. Your responsibilities are to purchase and transmit genetic information.
Since the early stages of the COVID-19 crisis, the Japan Times has provided free access to very important data on the effect of the new coronavirus, as well as practical data on how to deal with the pandemic. Please consider subscribing today so that we can continue to provide you with up-to-date and detailed information about Japan.
The Japan Times LTD. All rights reserved.